EML4 and neoplasm: However, the clinical benefit is often challenged by the emergence of resistance mechanisms and the complexities of tumor heterogeneity and spatial genomic diversity, exemplified by cases harboring concurrent fusions like EML4‐ALK and TPM3‐ROS1.